Cogent Biosciences Inc

NASDAQ COGT

Data sourced from

and

Download Data

Cogent Biosciences Inc Accounts Payable Turnover Ratio 1 year YoY Change (%) for the year ending December 31, 2021: -100.00%

Cogent Biosciences Inc Accounts Payable Turnover Ratio 1 year YoY Change (%) is -100.00% for the year ending December 31, 2021, a -291.86% change year over year. The accounts payable turnover ratio measures the number of times a company pays off its accounts payable during a specific period. It is calculated by dividing the company's revenue by its accounts payable. This ratio indicates how efficiently a company manages its outstanding payments to suppliers and vendors. A higher turnover ratio suggests that the company is paying off its obligations quickly, while a lower ratio may indicate a slower payment process or potential liquidity issues. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Cogent Biosciences Inc Accounts Payable Turnover Ratio for the year ending December 31, 2022 was 0.00, a 0.00% change year over year.
Cogent Biosciences Inc Accounts Payable Turnover Ratio for the year ending December 31, 2021 was 0.00, a -100.00% change year over year.
Cogent Biosciences Inc Accounts Payable Turnover Ratio for the year ending December 31, 2020 was 10.75, a 52.12% change year over year.
Cogent Biosciences Inc Accounts Payable Turnover Ratio for the year ending December 31, 2019 was 7.07, a 10.30% change year over year.

NASDAQ: COGT

Cogent Biosciences Inc

CEO	Mr. Andrew R. Robbins M.B.A.
IPO Date	March 29, 2018
Location	United States
Headquarters	200 Cambridge Park Drive, Cambridge, MA, United States, 02140
Employees	164
Sector	Healthcare
Industry	Biotechnology

Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Key trends